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Abstract
Background and objectives There is a need for local
anesthetics that provide consistent analgesia through
72 hours after surgery. This study evaluates the use of
HTX-011 (bupivacaine and meloxicam in Biochronomer
polymer technology), an extended-release, dual-acting
local anesthetic, in reducing both postoperative pain
over 72 hours and postoperative opioid use when
compared with bupivacaine hydrochloride (HCl) and
saline placebo. Inclusion of low-dose meloxicam in HTX011 is designed to reduce local inflammation caused by
surgery, potentiating the analgesic effect of bupivacaine.
Previously, significant synergy has been observed with
bupivacaine and meloxicam with both given locally
together.
Methods EPOCH 1 was a randomized, doubleblind, placebo-controlled and active-controlled phase
III study in subjects undergoing a primary unilateral,
distal, first metatarsal bunionectomy in which subjects
received either a single intraoperative dose of HTX-011,
immediate-release bupivacaine HCl or saline placebo.
Results A total of 412 subjects were dosed. The
results for the primary and all four key secondary
endpoints were statistically significant in favor of
HTX-011. HTX-011 demonstrated superior, sustained
pain reduction through 72 hours, significantly reduced
opioid consumption and resulted in significantly more
opioid-free subjects compared with saline placebo and
bupivacaine HCl. Safety was similar across groups with
fewer opioid-related adverse events observed in the HTX011 group.
Conclusions HTX-011 demonstrated significant
reduction in postoperative pain through 72 hours
with significant reduction in opioid consumption and
a significant increase in the proportion of opioid-free
subjects compared with saline placebo and the most
widely used local anesthetic, bupivacaine HCl.
Trial registration number NCT03295721.
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More than 500 000 bunionectomy procedures are
performed in the USA annually, making it one of
the most common surgeries. Patients most often
experience the greatest degree of pain within the
first 72 hours after surgery, with the majority
experiencing moderate to severe pain.1–5 Perioperative administration of local anesthetics such as
bupivacaine is commonly used in clinical practice
for managing postoperative pain; however, these

agents have shown limited efficacy beyond 6–12
hours, necessitating the use of additional postoperative analgesics, including opioids.6–8 Extended-release liposomal bupivacaine can potentially
extend the period of pain relief but rarely beyond
24 hours; it has not shown superiority to bupivacaine hydrochloride (HCl) in bunionectomy.6–8
There is a need for local anesthetics that can
provide consistent analgesia through the first 72
hours when patients experience the most severe
pain. Opioids are commonly used for postoperative pain management. The use of opioids is
associated with an increased risk of adverse drug
effects including respiratory depression, sedation, and postoperative nausea and vomiting.9 10
Across surgical models, poorly managed pain and
opioid-related adverse events (ORAEs) have been
shown to contribute directly to patient discomfort,
dissatisfaction, delayed recovery from surgery,
increased length of hospital stay and increased
medical costs.11–14
HTX-011 is a novel, extended-release, dualacting local anesthetic that is a fixed-dose combination of two active ingredients, bupivacaine and
low-dose meloxicam, incorporated in a proprietary
Biochronomer polymer. The product is a viscous
solution administered directly into the surgical
incision via a syringe with a Luer lock applicator
to coat the affected tissue prior to suturing. After
single-dose administration, the polymer enables
extended release of bupivacaine and meloxicam
simultaneously over approximately 3 days. Inclusion of low-dose meloxicam in HTX-011 reduces
local inflammation caused by surgery and normalizes the local pH,15 16 allowing the analgesic effect
of bupivacaine. This synergistic relationship has
been demonstrated in prior phase II studies in
bunionectomy and herniorrhaphy, where HTX-011
led to a substantially greater reduction in pain
intensity when compared with the same polymer
formulation containing either bupivacaine alone or
meloxicam alone.17
The objectives of this randomized, double-blinded,
placebo-controlled and active-controlled phase III
study (EPOCH 1) were to evaluate the analgesic
efficacy and safety of HTX-011 at a single dose of
60 mg/1.8 mg applied into the surgical site without
a needle, compared with bupivacaine HCl injection
(the most widely used local anesthetic for addressing
postoperative analgesia) and saline placebo in subjects
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Methods
Study design

The study was conducted at 13 sites across the USA from October
2017 to March 2018. All subjects provided written informed
consent prior to participation in any study-specific procedures.
Eligible subjects were required to be at least 18 years of age
with an American Society of Anesthesiologists physical status of I,
II or III. The study excluded subjects with a pre-existing, concurrent acute or chronic painful physical/restrictive condition that
could confound the postoperative assessments. Other key exclusion criteria included the use of non-steroidal anti-inflammatory
drugs (NSAIDs; including meloxicam) within 10 days prior to
the scheduled surgery, known or suspected daily use of opioids
for seven or more consecutive days within 6 months prior to
surgery, long-acting opioids within 3 days prior to surgery, the
use of any opioids within 24 hours prior to surgery, the administration of bupivacaine within 5 days prior to surgery and the
use of systemic steroids within five half-lives or 10 days prior to
administration of study drug.
Given the double-blind study design, neither the subjects nor the
investigators involved in conducting postsurgical assessments knew
which treatment was given. Subjects were randomly assigned using
a centralized computer-generated blocked randomization algorithm in a 3:3:2 ratio to three treatment groups: (A) HTX-011,
60 mg/1.8 mg (bupivacaine/meloxicam), 2.1 mL, applied into the
surgical site without a needle; (B) bupivacaine HCl 0.5%, 50 mg
(10 mL), via injection into the surgical site; and (C) saline placebo,
2.1 mL, applied into the surgical site without a needle. On day 1,
the day of surgery, subjects underwent a unilateral simple Austintype bunionectomy under regional anesthesia with no more than
20 mL of 1% lidocaine without epinephrine administered as
a Mayo block. Epidural or spinal anesthesia was not permitted.
During surgery, the use of opioids (other than intravenous fentanyl)
or other analgesics was prohibited.
Near the end of surgery, after irrigation and suction, a single
dose of study drug (HTX-011, bupivacaine HCl or saline placebo)
was administered intraoperatively via local application into the
surgical site by the investigator. Subjects remained in the hospital/
research facility for a minimum of 72 hours following surgery
to undergo postoperative assessments including pain intensity,
opioid use and collection of blood samples for assessment of
pharmacokinetics. Subjects could only receive rescue medication
on request to treat postoperative pain, not for pain prophylaxis,
during the 72 hours postoperative observation period. Postoperative rescue medication consisted of intravenous morphine (no
more than 10 mg within a 2-hour period as needed), oral oxycodone (no more than 10 mg within a 4-hour period as needed)
and/or oral acetaminophen (no more than 1000 mg in a 6-hour
window). No other analgesic agents were permitted. After the 72
hours, assessments were completed, subjects could be discharged
and were instructed to return to the study site on day 10, day 28
and day 42 to complete follow-up assessments. After discharge
through day 28, subjects were to complete a daily diary to record
whether they took opioids.

Outcome measures

The primary efficacy endpoint was mean area under the curve
(AUC) of the Numeric Rating Scale (NRS) of pain intensity
scores through 72 hours (AUC0-72) for HTX-011 compared with
saline placebo. During the first 72 hours following surgery, the
Viscusi E, et al. Reg Anesth Pain Med 2019;44:700–706. doi:10.1136/rapm-2019-100531

NRS was measured at hours 1, 2, 4, 8, 12, 24, 36, 48, 60 and 72.
Four key secondary efficacy endpoints were: (1) mean AUC0-72
of the NRS pain intensity scores for HTX-011 compared with
bupivacaine HCl, (2) mean total postoperative opioid consumption (in morphine milligram equivalents) through 72 hours for
HTX-011 compared with saline placebo, (3) the proportion of
subjects who were opioid free through 72 hours for HTX-011
compared with bupivacaine HCl and (4) the mean total postoperative opioid consumption (in morphine equivalents) through
72 hours for HTX-011 compared with bupivacaine HCl. To
account for multiple hypothesis testing on the primary endpoint
and on each of the four key secondary endpoints, a strict testing
hierarchy was applied to control study-wise alpha level at 0.05.
Other secondary efficacy endpoints included the proportion of
subjects with severe pain (defined as an NRS pain intensity score
≥7 at any timepoint through 72 hours) and the proportion of
subjects who were opioid free through 72 hours compared with
placebo, through day 10 and through day 28.
Safety endpoints included the incidence of treatment-emergent
adverse events (TEAEs), change from baseline in clinical laboratory results, ECG, vital signs, wound healing at 72 hours and 10,
28 and 42 days after treatment, bone-healing X-ray assessments at
28 and 42 days after treatment and ORAEs. ORAEs were based
on prespecified preferred adverse event (AE) terms of nausea,
vomiting, constipation, pruritus, pruritus generalized, somnolence,
respiratory depression and urinary retention, regardless of whether
a subject actually received an opioid medication.

Statistical analysis

Based on prior phase II studies of HTX-011 in subjects undergoing unilateral simple bunionectomy, a sample size of approximately 400 subjects (150, 150 and 100 in HTX-011, bupivacaine
HCl and saline placebo groups, respectively) was needed to
provide at least 90% power to detect a statistically significant
difference between the HTX-011 group and the control groups
for each of the primary and key secondary endpoints.
The primary and first key secondary endpoints were analyzed
using analysis of variance with treatment group as the main
effect, together with pairwise t tests to analyze differences
between treatment groups. Missing data, which were expected
to be very low due to the 72 hours hospitalization following
surgery, were imputed via last observation carried forward for
interval censored pain intensity scores and worst observation
carried forward (WOCF) for right-censored pain intensity scores
in the intent-to-treat (ITT) population. To adjust for the analgesic effect of opioid rescue medication, the windowed WOCF
method was implemented as the primary analysis method
in which pain intensity scores observed during the analgesic
window of any opioid rescue medication were replaced with the
worst postdose, non-missing NRS pain intensity score observed
prior to the rescue medication window. A sensitivity analysis
of the primary endpoint was performed with no adjustment
for opioid usage. The total postoperative opioid consumption
through 72 hours was analyzed using a Wilcoxon rank-sum test.
The proportion of subjects who were opioid free through 72
hours was analyzed using Fisher’s exact test. All TEAEs were
coded and tabulated by System Organ Class and Preferred Term.

Results
Baseline characteristics

Of 438 subjects who were randomly assigned to the three study
groups, 412 received one of the three interventions (ITT population; figure 1). Baseline disease characteristics were similar
701
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between groups and most of the subjects were female, as
expected given the surgical procedure (table 1).3

Efficacy findings: primary and secondary endpoints

HTX-011 demonstrated statistically significant as well as clinically relevant benefit for the primary endpoint and all four

Table 1

Baseline demographic by study group (ITT population)*

Baseline characteristics

Saline placebo
(n=100)

Bupivacaine HCl
50 mg
(n=155)

HTX-011
60 mg/1.8 mg
(n=157)

Age (years)
 Mean (SD)

47.3 (12.83)

45.5 (14.79)

48.0 (14.47)

 Min, max

19, 77

18, 77

18, 77

Sex, n (%)
 Female

86 (86.0)

132 (85.2)

138 (87.9)

 Male

14 (14.0)

23 (14.8)

19 (12.1)

2 (1.3)

1 (0.6)

Race, n (%)
 American Indian or Alaskan
Native
 Asian
 Black or African descent
 Native Hawaiian or another
Pacific Islander
 White
 Multiple

0
2 (2.0)

1 (0.6)

8 (5.1)

12 (12.0)

22 (14.2)

24 (15.3)

0
86 (86.0)
0

1 (0.6)

0

128 (82.6)

123 (78.3)

1 (0.6)

1 (0.6)

Ethnicity, n (%)
 Hispanic or Latino

32 (32.0)

49 (31.6)

47 (29.9)

 Not Hispanic or Latino

68 (68.0)

106 (68.4)

110 (70.1)

Body mass index (kg/m2)
 Mean (SD)

27.9 (5.05)

27.2 (4.38)

27.3 (4.79)

 Median

27.3

26.7

26.8

 Min, max

17.5, 38.4

17.3, 38.5

18.3, 38.6

*ITT population includes all subjects who were randomized and received study drug.
HCl, hydrochloride; ITT, intent to treat.
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key secondary endpoints (table 2). Compared with saline
placebo and bupivacaine HCl, application of HTX-011 resulted
in sustained pain reduction through 72 hours, significantly
less opioid consumption and significantly more subjects who
remained opioid free.
Subjects who received HTX-011 showed a reduction in mean
pain intensity over 72 hours of 27% compared with saline
placebo (323.3 vs 445.3; p<0.001; the primary endpoint)
and 18% compared with bupivacaine HCl (323.3 vs 393.5;
p<0.001; the first key secondary endpoint). Compared with
saline placebo, mean NRS pain intensity scores were lower
in the HTX-011 group at all timepoints through 72 hours. A
prespecified sensitivity analysis with no adjustment of opioid
use consistently showed significant pain reduction for HTX-011
compared with bupivacaine HCl and saline placebo (p<0.01 for
both comparisons), confirming the robustness of the results of
the primary analysis. Over the course of 72 hours after treatment, total opioid consumption was significantly reduced by
37% in those who received HTX-011 when compared with
saline placebo (p<0.001; the second key secondary endpoint)
and by 25% vs those who received bupivacaine HCl (p=0.002;
the fourth key secondary endpoint). Overall, 29% of subjects
who received HTX-011 were opioid free after 72 hours, whereas
11% of those who received bupivacaine HCl (p<0.001; the third
key secondary endpoint) and 2% of those who received placebo
(p<0.001) were opioid free (figure 2). In addition, a significantly
greater proportion of subjects who received HTX-011 were able
to go without any rescue medication, including acetaminophen.
After 72 hours, those treated with HTX-011 remained opioid
free at a significantly higher rate through day 10 and through
day 28 compared with subjects who received saline placebo or
bupivacaine HCl. Among the 45 HTX-011 subjects who were
opioid free during the 72 hours after surgery, 41 (91.1%) stayed
opioid free though day 10 and 37 (82.2%) stayed opioid free
though day 28.
Viscusi E, et al. Reg Anesth Pain Med 2019;44:700–706. doi:10.1136/rapm-2019-100531
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Figure 1 Consort flow diagram for EPOCH 1 study. HCl, hydrochloride; ITT, intent to treat; TEAE, treatment-emergent adverse event.
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Efficacy results for the primary and key secondary endpoints (ITT population)*

Endpoint

Saline placebo
(n=100)

Bupivacaine HCl
50 mg
(n=155)

HTX-011
60 mg/1.8 mg
(n=157)

445.3 (155.8)

393.5 (153.8)

323.3 (182.6)

AUC0-72 of the NRS pain intensity scores†
 Mean (SD)
 Primary endpoint: p value‡ versus saline placebo

<0.0001

 Secondary endpoint: p value‡ versus bupivacaine HCl

0.0002

Opioid consumption through 72 hours (MME)
 Mean (SD)

30.06 (21.01)

25.09 (21.55)

 Median (min, max)

25.0 (0, 80.0)

17.5 (0, 92.5)

 Secondary endpoint: p value§ versus saline placebo

18.80 (19.80)
12.5 (0, 83.0)
<0.0001

 Secondary endpoint: p value§ versus bupivacaine HCl

0.0022

Opioid free through 72 hours
 n (%)

2 (2.0)

17 (11.0)

 P value§ versus saline placebo

45 (28.7)
<0.0001

 Secondary end point: p value¶ versus bupivacaine HCl

0.0001

Opioid free through 72 hours is defined as subjects who had total MME opioid dose=0 from 0–72 hours. All doses of opioid rescue medication are expressed as intravenous MME.
*ITT population includes all subjects who are randomized and receive study drug. This population was used as the primary analysis population for all efficacy endpoints.
†Analyzed using wWOCF.
‡P values reflect results of an analysis of variance with randomized treatment as the main effect.
§P values were obtained using the Wilcoxon rank-sum test.
¶P values from Fisher's exact test.
AUC0-72, area under the curve through 72 hours; HCl, hydrochloride; ITT, intent to treat; MME, morphine milligram equivalent; NRS, Numeric Rating Scale of the pain intensity score; wWOCF,
windowed worst observation carried forward.

A separation in mean pain curves through 72 hours was
apparent between groups who received HTX-011, bupivacaine
HCl and saline placebo (figure 3). Fewer subjects in the HTX-011
group experienced severe pain (53.5%); this proportion was
significantly lower compared with saline placebo (83.0%) and
bupivacaine HCl (75.5%; p<0.001 for both comparisons)
(figure 3).
Subjects who received bupivacaine HCl experienced significantly lower pain in the first 12 and 24 hours after surgery
(AUC0-12 and AUC0-24) compared with those who received saline
placebo, but pain in those who received bupivacaine HCl was
not significantly different from placebo beyond 24 hours as
measured by AUC24-72 (table 3, figure 3).
By comparison, HTX-011 significantly reduced pain in the
first 12 and 24 hours versus both saline placebo and bupivacaine
HCl (AUC0-12 and AUC0-24; p<0.001 for both comparators),
and this reduction was maintained beyond 24 hours through

the full 72 hours period (AUC24-72; p<0.01 vs bupivacaine HCl;
p<0.001 vs placebo).

Safety
HTX-011 was well tolerated and exhibited a TEAE profile like
that of saline placebo and bupivacaine HCl (table 4).
The two most common TEAEs in the HTX-011 group were
nausea and dizziness. The incidence of nausea was numerically lower in the HTX-011 group compared with both the
saline placebo and bupivacaine HCl group (37.6% vs 43.6%
and 45.5%, respectively). There were no differences in serious
adverse events between groups, no drug-related serious adverse
events and no discontinuations due to drug-related adverse
events in the HTX-011-treated subjects. One death of unknown
cause occurred 17 days after a subject received bupivacaine
HCl and was deemed unlikely related to study drug. There was

Figure 2 Proportion of subjects experiencing severe pain at any time from 0 to 72 hours and proportion of subjects opioid free through 72 hours
(ITT population). HCl, hydrochloride; ITT, intent to treat.
Viscusi E, et al. Reg Anesth Pain Med 2019;44:700–706. doi:10.1136/rapm-2019-100531
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Overall summary of TEAE (safety population)*

TEAE, n (%)

Saline
placebo
(n=101)

Bupivacaine HCl HTX-011
50 mg
60 mg/1.8 mg
(n=154)
(n=157)

Any TEAE

79 (78.2)

131 (85.1)

131 (83.4)

Severe TEAEs

3 (3.0)

7 (4.5)

5 (3.2)

SAEs

1 (1.0)

3 (1.9)

3 (1.9)

Deaths

0

1 (0.6)

0

Drug-related SAEs

0

0

0

TEAEs leading to study
withdrawal

0

0

1 (0.6)

ORAEs†

Figure 3 Mean (SE) NRS pain intensity scores using wWOCF (ITT
population). HCl, hydrochloride; ITT, intent to treat; NRS, Numeric Rating
Scale; wWOCF, windowed worst observation carried forward.
no evidence of drug-related local anesthetic systemic toxicity
(LAST) based on a comprehensive review of TEAEs, vital signs,
ECGs and bupivacaine plasma concentrations (highest concentration observed was 190 ng/mL). The proportion of subjects
Table 3 Mean AUC of th NRS of pain intensity over time using
wWOCF (ITT population)*

Endpoint

Saline placebo
(n = 100)

Bupivacaine HCl
50 mg
(n = 155)

HTX-011
60 mg/1.8 mg
(n = 157)

AUC0-8
 Mean (SD)

37.55 (15.65)

 P value versus saline
placebo

24.26 (14.23)

20.68 (17.54)

<0.0001

<0.0001

 P value versus
bupivacaine HCl

0.0477

AUC0-12
 Mean (SD)

67.97 (22.98)

 P value versus saline
placebo

50.37 (22.94)

38.54 (28.08)

<0.0001

<0.0001

 P value versus
bupivacaine HCl

<0.0001

AUC0-24
 Mean (SD)

155.75 (48.49)

 P value versus saline
placebo

131.36 (48.86)
0.0004

 P value versus
bupivacaine HCl

98.65 (59.55)
<0.0001
<0.0001

AUC24-72
 Mean (SD)

289.59 (115.64)

 P value versus saline
placebo

262.09 (117.25)
0.0806

 P value versus
bupivacaine HCl

224.64 (131.28)
<0.0001
0.0072

AUC0-72
 Mean (SD)
 P value versus saline
placebo
 P value versus
bupivacaine HCl

445.34 (155.79)

393.45 (153.76)
0.0151

323.29 (182.64)
<0.0001
0.0002

*ITT population includes all subjects who are randomized and received study drug.
Analyzed using windowed worst observation carried forward (wWOCF). P values
reflect results of an analysis of variance with randomized treatment as the main
effect.
AUCx-y, area under the curve from x to y hours; HCl, hydrochloride; ITT, intent to
treat; NRS, Numeric Rating Scale.
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54 (53.5)

78 (50.6)

69 (43.9)

Nausea

44 (43.6)

70 (45.5)

59 (37.6)

Dizziness

18 (17.8)

36 (23.4)

34 (21.7)

Incision site edema

13 (12.9)

22 (14.3)

27 (17.2)

Vomiting

19 (18.8)

33 (21.4)

23 (14.6)

Most common TEAEs
(occurring in ≥15% of
subjects in any group)

Adverse events were coded to preferred term using the Medical Dictionary for
Regulatory Activities, version 19.1.
*Safety population includes all subjects who receive study drug, using actual
treatment received.
†Subjects reporting more than 1 ORAE are counted only once.
ORAEs, opioid-related adverse events; SAE, serious adverse event; TEAE, treatmentemergent adverse event.

reported to have any wound-healing findings was similar across
treatment groups. The most common wound-healing findings
across all treatment groups were bruising, erythema and edema,
with most resolving by the day 42 safety follow-up visit. There
was no evidence of drug-related delayed bone healing based
on X-rays through day 42 for all treatment groups. A lower
proportion of subjects experienced ORAEs in the HTX-011
group compared with the saline placebo and bupivacaine HCl
groups (43.9% vs 53.5% and 50.6%, respectively). No clinically
meaningful differences were observed between HTX-011, saline
placebo and bupivacaine HCl for other tested safety parameters
such as hematology and serum chemistry, vital signs and ECGs.

Discussion

In this phase III study, HTX-011 provided superior and sustained
pain reduction compared with bupivacaine HCl through the critical 72 hours postoperative window, when pain is often most
severe. HTX-011 is the only local anesthetic that has demonstrated such efficacy in a phase III study. Significant reductions
in pain occurred both early (in the first 24 hours) and were
sustained from 24 hours to 72 hours. In addition to reductions in
average pain scores, HTX-011 significantly reduced the proportion of patients ever experiencing severe pain through 72 hours.
The significant reductions in severe pain were consistent with
the significant increase in opioid-free subjects over that period,
and most subjects that required no opioids in the first 72 hours
continued to be opioid free through 28 days.
Bupivacaine HCl solution administered by standard infiltration technique was chosen as the active comparator in this study
because it accounts for approximately 70% of all local anesthetic usage in the USA (data on file). This study was powered
to demonstrate head-to-head superiority of HTX-011 60 mg/1.8
mg over bupivacaine HCl 50 mg using a statistically rigorous
gated approach. The finding that bupivacaine HCl significantly reduced pain in the first 12 and 24 hours versus placebo
confirmed that the selected 50 mg dose was appropriate. The
Viscusi E, et al. Reg Anesth Pain Med 2019;44:700–706. doi:10.1136/rapm-2019-100531
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scheduled multimodal analgesics (in order to assess the benefit
of HTX-011 alone postoperatively for regulatory requirements), addition of non-opioid analgesics would be expected
to further improve pain control and reduce opioid utilization.
Future studies incorporating other non-opioid agents are necessary to determine whether HTX-011 can serve as the keystone
of non-opioid pain protocol for patients undergoing foot and
ankle procedures.
In summary, the first 72 hours after surgery, when pain is
the most severe, is also the most crucial for pain management
and optimal patient recovery. Effective pain management and
reduced exposure to opioids are associated with improved
patient outcomes and reduced risk for ORAEs and the development of chronic opioid use. HTX-011, a dual acting local anesthetic, is the first locally administered product to demonstrate
superior, sustained pain reduction for 72 hours compared with
both saline placebo and bupivacaine. Furthermore, the superior
pain reduction with HTX-011 resulted in significantly fewer
subjects experiencing severe pain, leading to reduced opioid
consumption and a lower proportion of subjects who experienced ORAEs. Importantly, a significantly higher proportion
of subjects receiving HTX-011 had a completely opioid-free
recovery following surgery. In light of the current need within
the USA to reduce the amount of opioids prescribed to postsurgical patients, significant increases in the proportion of opioidfree patients may enable physicians to write fewer of these
prescriptions. HTX-011 was well tolerated with an AE profile
similar to saline placebo and bupivicaine.
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bone healing and is consistent with several studies showing that
short-term use of low-dose NSAIDs does not interfere with bone
healing.21–23
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